Inflacam (7 - 10 kg)
Active substance
ATC code
Species
Dogs
Indications
Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders.
Dose to be administered and administration route
Initial treatment is a single dose of 0.2 mg meloxicam/kg body weight on the first day.
Treatment is to be continued once daily by oral administration (at 24-hour intervals) at a maintenance dose of 0.1 mg meloxicam/kg body weight.
Each chewable tablet contains either 1 mg or 2.5 mg meloxicam, which corresponds to the daily maintenance dose for a 10 kg body weight dog, or a 25 kg body weight dog respectively.
Each chewable tablet can be halved for accurate dosing according to the individual body weight of the dog.
Inflacam chewable tablets can be administered with or without food, are flavoured and are taken by most dogs voluntarily.
Dose scheme for the maintenance dose:
Body weight Number of chewable tablets | mg/kg | ||
(kg) | 1 mg | 2.5mg | |
4.0–7.0 | ½ | 0.13–0.1 | |
7.1–10.0 | 1 | 0.14–0.1 | |
10.1–15.0 | 1½ | 0.15–0.1 | |
15.1–20.0 | 2 | 0.13–0.1 | |
20.1–25.0 | 1 | 0.12–0.1 | |
25.1–35.0 | 1½ | 0.15–0.1 | |
35.1–50.0 | 2 | 0.14–0.1 | |
The use of Inflacam oral suspension for dogs may be considered for an even more precise dosing. For dogs weighing less than 4 kg the use of Inflacam oral suspension for dogs is recommended.
A clinical response is normally seen within 3–4 days. Treatment should be discontinued after 10 days if no clinical improvement is apparent.
Adverse reactions
Typical adverse reactions of NSAIDs such as loss of appetite, vomiting, diarrhoea, faecal occult blood, lethargy and renal failure have occasionally been reported.
In very rare cases, haemorrhagic diarrhoea, haematemesis, gastrointestinal ulceration and elevated liver enzymes have been reported.
These side effects occur generally within the first treatment week and are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal.
If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
Similar products
Showing 2 of 2 results
Inflacam (7 - 10 kg)
